• 1
    Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry 1980; 37: 293297.
  • 2
    Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 13931394.
  • 3
    Chan WY, Setter SM, Sclar DA, Salek S, Corbett C, Henliksen AL. The use of anticholinergic medications in homebound elderly patients with dementia. Consult Pharm 2006; 21: 391399.
  • 4
    Huey ED, Taylor JL, Luu P, Oehlert J, Tinklenberg JR. Factors associated with use of medications with potential to impair cognition or cholinesterase inhibitors among Alzheimer's disease patients. Alzhemer's Dementia 2006; 2: 314321.
  • 5
    Mulsant BH, Pollock BG, Kirshner M, Shen C, Dogde H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry 2003; 60: 198203.
  • 6
    Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL. Anticholinergic sensitivity in patients with dementia of Alzheimer type and age-matched control: a dose-response study. Arch Gen Psychiatry 1987; 444: 418426.
  • 7
    Thienhause OJ, Allen A, Bennett JA, Chopra YM, Zemlan F. Anticholinergic serum levels and cognitive performance. Eur Arch Clin Neurosci 1990; 240: 2833.
  • 8
    Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1998; 24: 189198.
  • 9
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force in Alzheimer's disease. Neurology 1984; 56: 939944.
  • 10
    Folstein MF, Folstein SE, M Hugh RP. ‘Mini-Mental State.’ A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975; 12: 95112.
  • 11
    Tune LE, Damlouji NF, Holland A, Gardner TJ, Folstein MF, Coyle JT. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 1981; 8248: 651653.
  • 12
    Postmianos G, Kellett M. Anti-cholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients. Br J Psychiat 1982; 140: 470472.
  • 13
    Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 16911698.
  • 14
    Flacker JM, Lipsitz LA. Serum anticholinergic activity changes with acute illness in elderly medical patients. J Geront Med Sci 1999; 54: M12M16.
  • 15
    Rovner BW, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care capacity and anticholinergic drug levels in nursing home patients. Am J Psychiatry 1988; 145: 107109.
  • 16
    Tollesfon GD, Montague-Clouse J, Lancaster SP. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991; 3: 314319.
  • 17
    Remillard AJ. A pilot project to assess the association of anticholinergic symptoms with anticholinergic serum levels in the elderly. Pharmacotherapy 1994; 41: 482487.
  • 18
    Chew ML, Mulsant BH, Pollock BG, CPAD Study group. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry 2005; 13: 535538.
  • 19
    Ihara H, Arai H. Ethical dilemma associated with the off-label use of antipsychotic drugs for the treatment of behavioral and psychological symptoms of dementia. Psychogeriatrics 2008; 8 (1): 3237.
  • 20
    Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelly M. Cognitive impairment following benzodiabepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 8993.
  • 21
    Tonne U, Hiltunen AJ, Vikander B et al. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiabepine dependent patients. Acta Psychiatr Scand 1995; 299304.
  • 22
    Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Nerol 2003; 54: 235238.
  • 23
    Lu C-J, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer's disease. Am J Geriatr Psychiatry 2003; 11: 458461.
  • 24
    Rockwood K. Acute confusion in elderly medical patients. J Am Geriatr Soc 1989; 37: 150154.
  • 25
    Hori K, Funaba Y, Konishi K et al. Assessment of pharmacological toxicity using serum anticholinergic activity in a patient with dementia. Psychiatry Clin Neurosci 2005; 59: 508510.
  • 26
    Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatr Soc 1988; 36: 16.
  • 27
    Hope T, Keene J, Gedling K, Cooper S, Fairburn C, Jacoby AD. Behavior changes in the dementia 1: point of entry data a prospective study. Int J Geriatr Psychiatry 1997; 12: 10621073.
  • 28
    Nagaratnam N, Lewis-Jones M, Scott D, Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis Assoc Disord 1998; 12: 330334.